Nebivolol is NOT recommended during breastfeeding
You should not breastfeed while using nebivolol. The FDA drug label explicitly states that "it is not known if nebivolol passes into your breast milk" and directly advises that "you should not breastfeed while using nebivolol tablets" 1. This represents the highest-quality, most authoritative guidance available.
Why Nebivolol Should Be Avoided
The FDA labeling clearly indicates insufficient safety data for nebivolol during lactation 1. While animal studies show nebivolol is present in rat milk at 4 hours post-dose (with pups ingesting 0.3% of the maternal dose), there is no human data on milk transfer, infant exposure levels, or clinical effects on breastfed infants 1.
Beta-blockers as a class carry specific concerns during nursing, particularly the risk of bradycardia (slow heart rate) in infants, which can be serious 1. The FDA explicitly warns that "because of the potential for β-blockers to produce serious adverse reactions in nursing infants, especially bradycardia, nebivolol tablets are not recommended during nursing" 1.
Better Alternatives for Breastfeeding Mothers
Recent 2025 guidelines provide clear, evidence-based alternatives for treating hypertension during breastfeeding 2:
First-Line Safe Options (with documented low infant exposure):
- Labetalol - Safe; RID 3.6% 2
- Nifedipine XL - Safe; RID 2.3%-3.4% 2
- Enalapril - Safe; RID 1.1% 2
- Amlodipine - Safe; RID 1.7%-4.3% 2
Other Safe Alternatives:
- Methyldopa - Well-established safety profile 2, 3
- ACE inhibitors (enalapril preferred) - Low milk-to-plasma ratios 3
- Calcium channel blockers with documented safety 2, 3
Key Clinical Considerations
Relative Infant Dose (RID) levels <10% are considered safe 2. The medications listed above all have documented RIDs well below this threshold. In contrast, nebivolol has no established RID because human lactation data simply doesn't exist 1.
Older research from 2002 suggests that beta-blockers with low protein binding have higher milk-to-plasma ratios and should be avoided, while those with high protein binding appear safer 3. However, without specific data on nebivolol's behavior in human milk, this cannot guide decision-making for this particular agent.
Common Pitfall to Avoid
Do not assume that because other beta-blockers (like labetalol or metoprolol) have some safety data during lactation, nebivolol can be used. Each beta-blocker has unique pharmacokinetic properties that affect milk transfer differently 3. The absence of human lactation data for nebivolol, combined with the FDA's explicit recommendation against its use, makes it inappropriate for breastfeeding mothers.
Switch to a documented safe alternative (labetalol, nifedipine XL, or enalapril as first-line options) before initiating or continuing breastfeeding 2.